ライフサイエンスコーパス: S1P

1 S1P can bind to several G-protein-coupled receptors (GPC

2 S1P deficiency aggravated vasoplegia in this model, argu

3 S1P deficiency impaired aggregation and spreading of was

4 S1P did not increase production of this pro-inflammatory

5 S1P exerts its effects in S1P receptor-independent manne

6 S1P induced SynI relocation to extrasynaptic regions of

7 S1P is a ligand for five G-protein-coupled receptors, S1

8 S1P levels within the mammalian host are tightly regulat

9 S1P production was selectively impaired in mouse platele

10 S1P promotes cell growth, survival, and migration and is

11 S1P serum level in humans was correlated with endothelia

12 S1P signalling maintains the mitochondrial content of na

13 S1P-induced SynI relocation occurred in a Ca(2+)-indepen

14 S1P-R1 and Kruppel-like factor 2 expression were monitor

15 S1P-R1 was the prevalent S1P receptor on mature human th

16 resulted in a fully mature and active SKI-1/S1P chimera.

17 GPC-derived target sequences by human SKI-1/S1P in a quantitative manner.

18 Our study suggests that primordial SKI-1/S1P likely contained a simpler prodomain consisting of t

19 Notably, SKI-1/S1P of arthropods, like the fruit fly Drosophila melanog

20 cover a modular structure of the human SKI-1/S1P prodomain and define its function in folding and act

21 Zymogen activation of SKI-1/S1P requires removal of an N-terminal prodomain, by a mu

22 eloped cell-based molecular sensor for SKI-1/S1P to characterize the processing of arenavirus GPC-der

23 ver, little is known about the role of the 2 S1P-specific phosphohydrolase isoforms, SGPP1 and SGPP2,

24 und that Th17 cells egress from the gut in a S1P-receptor-1-dependent fashion and subsequently migrat

25 were abolished following administration of a S1P receptor 2 (S1P2) antagonist or a PI3K inhibitor.

26 Knockdown of either MRTF-A or YAP abrogates S1P-stimulated CCN1 expression, demonstrating that both

27 ike factor 2 expression were monitored after S1P exposure by using flow cytometry and quantitative PC

28 s QSG-7701's proliferation, in which AKR1B10-S1P signaling plays a pivotal role.

29 Pretreatment with FTY720, an S1P-R1 nonselective modulator significantly reduced migr

30 which was partially rescued by VPC23109, an S1P receptor antagonist.

31 ockdown (TRPC1-KD) ML-1 cells, the basal and S1P-evoked invasion and migration was attenuated.

32 ic process and suggest that p120 catenin and S1P/S1pr2 signaling enhance cancer progression by regula

33 We describe MC and S1P as novel pathogenic effectors that initiate remodeli

34 There are 5 known S1P receptors, and S1P induces adherens junction formation between endothel

35 transporter, spinster homolog 2 (Spns2), and S1P receptor, S1P1, in lamellipodia formation and perhap

36 We used a highly specific neutralizing anti-S1P antibody (mAb) and the sphingosine-1-phosphate recep

37 Reconstitution of plasma ApoM/S1P or treatment with an S1P1 receptor agonist (SEW2871)

38 ical inhibitors of the Hippo pathway such as S1P recover the ER instability and necrosis in HD model

39 ted that inhibition of SphK2 increases blood S1P levels.

40 Phosphate moiety of the surface bound S1P engages in a highly positive region close to alpha1-

41 naive T cells were readily chemoattracted by S1P in an FTY720-sensitive, S1PR1-dependent manner.

42 er, we show that early activation of RhoA by S1P inactivates Rac1 but not Cdc42, and vice versa.

43 lowed by proteolytic activation of SREBPs by S1P and S2P in the Golgi.

44 In these cells, S1P, but not TNF, promotes IkappaB kinase (IKK) and p65

45 MI HF progression in mice as much as chronic S1P treatment.

46 R knockout mice does not elevate circulating S1P levels, nor does it ameliorate post-MI dysfunction,

47 eta1AR-blockers display elevated circulating S1P levels, confirming that Meto promotes S1P secretion/

48 Circulatory S1P has critical roles in maturation and homeostasis of

49 Thus, circulatory S1P confinement could be a primordial strategy of verteb

50 Constitutive S1P-R expression was quantified by means of real-time PC

51 te (S1P) signaling via the G protein-coupled S1P receptor 1 in these progenitors.

52 These compounds effectively decrease S1P levels in vitro.

53 ypes, including a delay in epiboly, depleted S1P levels, elevated levels of sphingosine, and resistan

54 dered both platelet- and erythrocyte-derived S1P essential for survival, with a contribution from blo

55 urkholderia-infected macrophages with either S1P or a selective agonist of S1P receptor 1 enhanced ba

56 inase-2 deficient mice had higher endogenous S1P levels and the LPS/PepG-induced impaired systolic co

57 ect SynI distribution and whether endogenous S1P could be involved in the process.

58 lly manipulating the S1P-metabolizing enzyme S1P lyase (SPL).

59 Here, we report that increased erythrocyte S1P binds to deoxygenated sickle Hb (deoxyHbS), facilita

60 abolomic profiling, we show that erythrocyte S1P levels rapidly increase in 21 healthy lowland volunt

61 source redundancy normally secures essential S1P signaling in developing and mature blood vessels, pr

62 ocyte population or populations that express S1P-Rs and respond to S1P by migrating across a concentr

63 egulated genes in various cell types and for S1P-stimulated glioblastoma cell proliferation.

64 egia in this model, arguing a vital role for S1P in maintaining vascular resistance during recovery f

65 ion and reveal a previously unknown role for S1P in positioning cells within the medulla.

66 These results indicate a role for S1P signaling in B. pertussis-mediated pathology and hig

67 y reduced migration and suggested a role for S1P-R2 in retaining thymocytes in the tissue.

68 YAP associate in coimmunoprecipitations from S1P-stimulated cells.

69 ates thymic exit via a process distinct from S1P-mediated migration.

70 ociated with reduced survival signaling from S1P receptor 2, resulting in selective downregulation of

71 y inhibiting SPHK1 activity, which generates S1P.

72 liver tissue from mice and patients, hepatic S1P levels increased owing to increased hepatic sphingos

73 ed with WT ECs, resulting in a 2-fold higher S1P level.

74 nhibitors of sphingolipid cascade identified S1P as the sphingolipid mediating SynI redistribution.

75 Recently, we identified S1P as an acute ERM activator (via phosphorylation) thro

76 s tumour aggressiveness in OSCC and identify S1P signalling as a potential therapeutic target.

77 These findings identify S1P metabolism as a novel player in modulating synaptic

78 S1P exerts its effects in S1P receptor-independent manner.

79 est that Galphaq activity is not involved in S1P-mediated regulation of barrier integrity.

80 f inflammation and associated with increased S1P generation.

81 Mechanistically, we found that Meto-induced S1P secretion is beta3AR-dependent because Meto infusion

82 show that elevated erythrocyte Sphk1-induced S1P protects against tissue hypoxia by inducing O2 relea

83 attractive chemotypes capable of inhibiting S1P formation in cells.

84 a SphK1, which was mediated by intracellular S1P, independent of S1P receptors.

85 1 phosphorylation and enhanced intracellular S1P levels in HLMVECs, which was blocked by inhibition o

86 activation of SphK1, increased intracellular S1P, and up-regulated expression of SphK1, Col alpha1(I)

87 e, we investigated the role of intracellular S1P in insulin-secreting INS1E cells by genetically mani

88 Mechanistically, we show that intracellular S1P promotes deoxygenated Hb anchoring to the membrane,

89 Intriguingly S1P completely stops the decline of motor function of HD

90 PL), the enzyme responsible for irreversible S1P cleavage was inactivated.

91 lbumin-sized particles in ApoM deficiency is S1P- and S1P1-dependent and this dependency exacerbates

92 There are 5 known S1P receptors, and S1P induces adherens junction formati

93 eversible degradation of the bioactive lipid S1P.

94 he use of a reporter for the signaling lipid S1P (sphingosine 1-phosphate), we found that cells sense

95 , which contributed to a reduced liver:lymph S1P gradient and limited HSC egress from the liver.

96 a subset of tumours, which in part mediates S1P-induced migration of OSCC cells.

97 cantly reduces expression of genes mediating S1P/S1pr2 signaling in vivo and in vitro, and this effec

98 We have shown previously that neuronal S1P accumulation is toxic leading to ER-stress and an in

99 of fingolimod was found to be a nonselective S1P receptor agonist, agonism specifically of S1P1 is re

100 L(fl/fl/CaMK)) caused marked accumulation of S1P.

101 re completely abrogated by the activation of S1P/S1pr2 signaling.

102 y regulated, in part through the activity of S1P lyase (S1PL) which catalyses its irreversible degrad

103 es with either S1P or a selective agonist of S1P receptor 1 enhanced bacterial colocalisation with LA

104 Fourteen fluorine-containing analogues of S1P ligands were synthesized and their in vitro binding

105 tor mediated most of the survival benefit of S1P, whereas the endothelial S1P1 receptor was dispensab

106 The concentration of S1P is higher in circulatory fluids than in lymphoid org

107 d that cells sensed higher concentrations of S1P in the medullary cords than in the T cell zone and t

108 dy, we have investigated the contribution of S1P signalling to the pathogenesis of OSCC.

109 -013 to study the signaling contributions of S1P and S1PR2 to MC- and IgE-dependent airway allergic r

110 ases in ceramide and consequent decreases of S1P reduce proliferation of various cancers, AC might of

111 d SGPP2, which catalyze dephosphorylation of S1P to sphingosine.

112 lung epithelial cells in a manner devoid of S1P agonism.

113 To clarify the neuronal function of S1P, we generated brain-specific knockout mouse models i

114 Physiological functions of S1P are tightly linked to shear stress, the key biophysi

115 is dependent on intracellular generation of S1P via activation and localization of SphK1 to cell per

116 The relative importance of S1P sources sustaining these processes remains unclear.

117 Incubation of S1P with airway smooth muscle cells significantly increa

118 ediated by intracellular S1P, independent of S1P receptors.

119 hat SPL's pro-IFN function is independent of S1P.

120 Inhibition of S1P signaling has been proposed as a strategy for treatm

121 Pharmacological inhibition of S1P synthesis reduced vasoconstriction of mesenteric art

122 The interaction of S1P with the S1P receptors plays a fundamental physiolog

123 Herein, we investigated the involvement of S1P in human liver fibrosis.

124 Cohort (n = 6099), suggesting involvement of S1P signalling in human hearing loss.

125 Interestingly, the level of S1P was also higher in PHC tissues than in peri-tumor ti

126 t it is caused by decreased plasma levels of S1P and reduced S1P1 stimulation.

127 Levels of S1P in liver, bone marrow, and lymph fluid were measured

128 In this work, we dissect the mechanism of S1P generation downstream of epidermal growth factor (EG

129 ro-survival actions seen after modulation of S1P-metabolizing enzymes allows this axis to emerge as a

130 We demonstrate a novel outcome of S1P-mediated regulation of lymphocyte trafficking, where

131 is, further highlighting the pivotal role of S1P in host-pathogen interactions.

132 lso challenge previous models of the role of S1P in lymphocyte recirculation and suggest that S1P pro

133 s, neither platelets nor any other source of S1P was essential for vascular development, vascular int

134 As the key mediators in the synthesis of S1P, sphingosine kinase (SphK) isoforms 1 and 2 have att

135 esicles for exocytosis, as the key target of S1P action.

136 study was to identify presynaptic targets of S1P action controlling exocytosis.

137 ns2-mediated extracellular transportation of S1P and its inside-out signaling via S1P1.

138 Mature human thymocytes rely on S1P-R1 to migrate toward S1P.

139 apeutically antagonizing TNF (etanercept) or S1P (JTE013) signaling corrects this defect.

140 BH3 mimetics with either SPHK1 inhibition or S1P receptor 2 antagonism triggered synergistic AML cell

141 equired for transcriptional control of other S1P-regulated genes in various cell types and for S1P-st

142 vity on S1P1 while sparing activity on other S1P receptors could offer equivalent efficacy with reduc

143 mation, suggesting a key role for inside-out S1P signaling.

144 ingosine and its metabolite sphingosine-1-P (S1P) stimulate excitatory transmission.

145 ing evidence indicates that sphingosine-1-P (S1P) upregulates glutamate secretion in hippocampal neur

146 1P egress signal, whereas thymic parenchymal S1P levels are kept low through S1P lyase (SPL)-mediated

147 at deficiency of the sphingosine-1-phoshate (S1P) transporter gene Spns2 in endothelium increased imm

148 The role of sphingosine-1 phosphate (S1P) in leukocyte trafficking has been well deciphered i

149 ations of SphK1 and sphingosine 1 phosphate (S1P).

150 the bioactive lipid sphingosine 1-phosphate (S1P) and has established roles in tumor initiation, prog

151 active sphingolipid sphingosine-1-phosphate (S1P) and the kinase that produces it have been implicate

152 the lipid mediator sphingosine-1-phosphate (S1P) are reduced in septic patients and are inversely as

153 ctivation and local sphingosine-1-phosphate (S1P) are significantly augmented after OVA treatment in

154 duced intracellular sphingosine-1-phosphate (S1P) generation catalyzed by sphingosine kinase 1 (SphK1

155 chemotaxis along a sphingosine-1-phosphate (S1P) gradient.

156 The chemoattractant sphingosine 1-phosphate (S1P) guides T cell circulation among secondary lymphoid

157 phospholipids like sphingosine-1-phosphate (S1P) in AKR1B10's oncogenic function.

158 M (ApoM) transports sphingosine-1-phosphate (S1P) in plasma, and ApoM-deficient mice (Apom(-/-)) have

159 Chronic sphingosine-1-phosphate (S1P) infusion resulted in a development of significantly

160 Sphingosine 1-phosphate (S1P) is a bioactive lipid that interacts with cell-surfa

161 Sphingosine-1-phosphate (S1P) is a bioactive signalling lipid highly enriched in

162 Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulat

163 The bioactive lipid sphingosine 1-phosphate (S1P) is a degradation product of sphingolipids that are

164 Sphingosine 1-phosphate (S1P) is a multifunctional bioactive sphingolipid involve

165 Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule that interacts

166 Sphingosine 1-phosphate (S1P) is a sphingolipid and the natural ligand for five G

167 Elevated sphingosine 1-phosphate (S1P) is detrimental in Sickle Cell Disease (SCD), but th

168 Sphingosine-1-phosphate (S1P) is generated through phosphorylation of sphingosine

169 Sphingosine 1-phosphate (S1P) is the endogenous ligand for the sphingosine 1-phos

170 Here, we show that sphingosine 1-phosphate (S1P) levels are not only increased in palmitate-stimulat

171 Sphingosine 1-phosphate (S1P) lyase (SPL) is an intracellular enzyme that mediate

172 GPL1, which encodes sphingosine-1-phosphate (S1P) lyase.

173 the lipid mediator sphingosine 1-phosphate (S1P) may be one such mechanism.

174 Sphingosine-1-phosphate (S1P) mediates egress of immune cells from the lymphoid o

175 rray data indicated sphingosine 1-phosphate (S1P) metabolism and signalling was deregulated in OSCC.

176 Rs for thrombin and sphingosine-1-phosphate (S1P) on human glioblastoma cells robustly couple to RhoA

177 ndependently of the sphingosine 1-phosphate (S1P) pathway was unknown.

178 Sphingosine 1-phosphate (S1P) produces significant endothelial barrier enhancemen

179 phingosine used for sphingosine-1-phosphate (S1P) production.

180 ed the potential of sphingosine 1-phosphate (S1P) receptor (S1PR) agonism in the treatment of infecti

181 ng mutations in the sphingosine-1-phosphate (S1P) receptor 2 (S1PR2) promoter have been associated wi

182 he cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1).

183 role of endothelial sphingosine 1-phosphate (S1P) receptor-1, a G protein-coupled receptor known to p

184 Modulation of sphingosine 1-phosphate (S1P) receptors in a non-selective manner decreases disea

185 ion and function of sphingosine-1-phosphate (S1P) receptors in human thymocyte egress.

186 Sphingosine-1-phosphate (S1P) signaling is essential for vascular development and

187 drug FTY720 affects sphingosine-1-phosphate (S1P) signaling on targeted cells that bear the S1P recep

188 velopment, required sphingosine 1-phosphate (S1P) signaling via the G protein-coupled S1P receptor 1

189 c tone via enhanced sphingosine-1-phosphate (S1P) signaling.

190 The sphingolipid sphingosine-1-phosphate (S1P) signals through five G-protein-coupled receptors (S

191 Because sphingosine-1-phosphate (S1P) strengthens AJs, we determined if TRPC1 functioned

192 sis was observed in sphingosine-1-phosphate (S1P) transporter spinster homologue 2 (Spns2)-deficient

193 However, levels of sphingosine-1-phosphate (S1P) were significantly increased in Ormdl3(Delta2-3/Del

194 2 (SK2) synthesize sphingosine-1-phosphate (S1P), a bioactive lipid messenger critically involved in

195 Sphingosine-1-phosphate (S1P), a bioactive sphingolipid metabolite, plays a criti

196 ve bioactive lipid, sphingosine-1-phosphate (S1P), could ameliorate the microvascular leakage followi

197 n be metabolized to sphingosine-1-phosphate (S1P), linked to inflammation and tumorigenesis.

198 d the metabolism of Sphingosine-1-phosphate (S1P), one of the most important bioactive lipids, in bot

199 h cl-CD95L produced sphingosine-1-phosphate (S1P), which promoted endothelial transmigration by activ

200 nced sensitivity to sphingosine 1-phosphate (S1P).

201 ed receptor agonist sphingosine-1-phosphate (S1P).

202 -signaling molecule sphingosine-1-phosphate (S1P).

203 de (-50 +/- 3%) and sphingosine 1-phosphate (S1P, -40 +/- 4%), which ended up to reduction in cell mo

204 bioactive sphingosine-1-phosphatephosphate (S1P) is present in plasma, bound to carrier proteins, an

205 necessary for recovery and high basal plasma S1P levels protective during anaphylactic shock.

206 Yet rapid and profound depletion of plasma S1P during systemic anaphylaxis rendered both platelet-

207 blood vessels, profound depletion of plasma S1P renders both erythrocyte and platelet S1P pools nece

208 (-/-)) have approximately 50% reduced plasma S1P levels.

209 ma S1P renders both erythrocyte and platelet S1P pools necessary for recovery and high basal plasma S

210 spirin in mice with but not without platelet S1P, suggesting that platelet activation and stimulus-re

211 We show that LpSpl possesses S1P lyase activity that was abrogated by mutation of the

212 S1P-R1 was the prevalent S1P receptor on mature human thymocytes (CD3(hi)CD27(+)C

213 ng S1P levels, confirming that Meto promotes S1P secretion/signaling.

214 report that the Arabidopsis SITE-1 PROTEASE (S1P) cleaves endogenous RAPID ALKALINIZATION FACTOR (RAL

215 sin kexin isozyme-1 (SKI-1)/site-1 protease (S1P) is implicated in lipid homeostasis, the unfolded pr

216 sin kexin isozyme 1 (SKI-1)/site 1 protease (S1P).

217 Together, our data show that the rapid S1P-induced increase in endothelial integrity is mediate

218 We aimed to determine whether S1P receptors (S1P-Rs) play a role in mature human thymocyte egress and

219 ssion of the two major enzymes that regulate S1P levels were altered in OSCC: SPHK1 was significantly

220 t, FTY720 and FTY720-P significantly repress S1P-induced IL-6 and IL-8 production.

221 Altogether, we reveal S1P as an intracellular hypoxia-responsive biolipid prom

222 support the survival of T cells by secreting S1P via the transporter SPNS2, that this S1P signals thr

223 he safety and efficacy of the oral selective S1P receptor modulator ozanimod in patients with relapsi

224 gical or genetic approaches that alter serum S1P may attenuate cardiac dysfunction and whether S1P si

225 e that activation of S1P2 by increased serum S1P and the subsequent activation of the PI3K-Akt surviv

226 f the immunomodulator FTY720 increased serum S1P, improved impaired systolic contractility and activa

227 red systolic contractility and reduced serum S1P.

228 We show that serum S1P is reduced in human sepsis and in murine models of s

229 mphatic circulation, thus comprising a sharp S1P gradient across the endothelial barrier.

230 uffice to activate local MC and elevate skin S1P.

231 Furthermore, skin S1P levels remain unchanged in MC-deficient mice exposed

232 n catalyzed by sphingosine kinase 1 (SphK1), S1P transporter, spinster homolog 2 (Spns2), and S1P rec

233 In in vitro studies, S1P enhanced the migration/invasion of OSCC cells and at

234 Lastly, surface S1P-R1 expression, as well S1PR1 and Kruppel-like factor

235 Surprisingly, S1P had the opposite effect on effector memory T cells,

236 tructure at 1.9 A resolution deciphered that S1P binds to the surface of 2,3-BPG-deoxyHbA and causes

237 We also demonstrate that S1P receptor expression is deregulated in primary OSCCs

238 of the CCN1 gene promoter demonstrated that S1P increases coactivator binding at the canonical trans

239 Here, we demonstrated that S1P metabolism is significantly disrupted in HD even at

240 he context of murine work demonstrating that S1P is required for thymocyte egress to the periphery, o

241 data represent the first demonstration that S1P induces SynI mobilization from synapses, thereby ind

242 In addition, we provide evidence that S1P can be produced at mature axon terminals as well as

243 We next found that S1P effectively could reverse alcohol-induced endothelia

244 Lastly, we observed that S1P administration ameliorated hypotension and microvasc

245 Functional studies revealed that S1P and 2,3-BPG work synergistically to decrease both Hb

246 Here we show that S1P is essential not only for the circulation of naive T

247 We show that S1P promotes cell spreading and endothelial barrier func

248 Taken together, our data show that S1P signalling promotes tumour aggressiveness in OSCC an

249 lysis of rat hippocampal neurons showed that S1P applied at nanomolar concentration alters the distri

250 , vascular transcriptome analysis shows that S1P pathway is critical in the regulation of vascular fu

251 The present study shows that S1P stimulation of human, primary pDCs substantially dec

252 In addition, our data suggest that S1P pathway modulators have potential for the treatment

253 in lymphocyte recirculation and suggest that S1P promotes retention of memory T cell subsets in secon

254 The S1P signalling pathway is being targeted therapeutically

255 eficiency in sphingosine kinase (SphK)1, the S1P-producing enzyme, or in MC, remarkably mitigates all

256 endothelial transmigration by activating the S1P receptor 3.

257 P) signaling on targeted cells that bear the S1P receptors S1P1, S1P3, S1P4, and S1P5.

258 an TECs or other stromal cells, disrupts the S1P gradient, preventing egress.

259 Mice given the S1P antagonist (FTY720) with HSCs had increased hepatic

260 However, the S1P degradation-incompetent form of SPL also enhanced IF

261 INS1E cells by genetically manipulating the S1P-metabolizing enzyme S1P lyase (SPL).

262 sses the cellular and molecular basis of the S1P gradients and aims to interpret its physiological si

263 essels) and underscore the importance of the S1P pathway in vascular development.

264 We found that genetic deletion of the S1P receptor 1 (S1pr1) alone in CD11b(hi) CD206(+) TAMs

265 that expression of SPNS2, expression of the S1P receptor S1PR5 on NK cells, and expression of the ch

266 In an attempt to investigate the role of the S1P/S1P2 axis in vivo, the New Zealand obese (NZO) diabe

267 at the corticomedullary junction produce the S1P egress signal, whereas thymic parenchymal S1P levels

268 y cords than in the T cell zone and that the S1P transporter SPNS2 on lymphatic endothelial cells gen

269 The interaction of S1P with the S1P receptors plays a fundamental physiological role in

270 cells from C57BL6 mice, with or without the S1P antagonist FTY720; we then studied HSC mobilization

271 ovel role for Abl kinases in mediating these S1P effects.

272 ing S1P via the transporter SPNS2, that this S1P signals through S1P1R on T cells, and that the requi

273 parenchymal S1P levels are kept low through S1P lyase (SPL)-mediated metabolism.

274 sion is NF-kappaB-dependent, and unlike TNF, S1P did not activate NF-kappaB.

275 herapies for humans with hearing loss due to S1P signalling defects need to target strial function.

276 Human thymocytes were exposed to S1P in Transwell plate migration assays coupled to flow

277 ecreased in mature thymocytes on exposure to S1P.

278 t as ceramides, but cannot be metabolized to S1P.

279 pulations that express S1P-Rs and respond to S1P by migrating across a concentration gradient.

280 t also demonstrated the greatest response to S1P in migration assays.

281 s study, we assessed the ex vivo response to S1P of primary human T cell subsets.

282 o flow cytometry to evaluate the response to S1P of thymocytes at different stages of maturation.

283 but not blood leukocytes were responsive to S1P gradients, suggesting that T cell responsiveness is

284 thymocytes rely on S1P-R1 to migrate toward S1P.

285 ) expression and diminished migration toward S1P in the Pparg(C/-) splenocytes, which impeded lymphoc

286 e functional and structural bases underlying S1P-mediated pathogenic metabolic reprogramming in SCD a

287 Unexpectedly, S1P also enhances MRTF-A binding at TEA sites.

288 0 and FTY720-P with S1P, we show that unlike S1P, the sphingosine analogs do not induce cytokine prod

289 In vertebrates, S1P is spatially compartmentalized in the blood and lymp

290 FTY720 triggers MDSCs to release GM-CSF via S1P receptor 3 (S1pr3) through Rho kinase and extracellu

291 We found that whereas S1P promotes IL-1-induced expression of IL-6, it inhibit

292 ay attenuate cardiac dysfunction and whether S1P signaling might serve as a novel theragnostic tool i

293 We aimed to determine whether S1P receptors (S1P-Rs) play a role in mature human thymo

294 To examine whether S1P contributes to the morphologic changes of islets via

295 complexes, the molecular mechanism by which S1P promotes neurotransmission remained largely undefine

296 rain-specific knockout mouse models in which S1P-lyase (SPL), the enzyme responsible for irreversible

297 osphoprotein as a novel target through which S1P controls exocytosis.

298 ever, the molecular mechanisms through which S1P enhances excitatory activity remain largely undefine

299 ultiple cytoskeletal changes associated with S1P-mediated endothelial barrier enhancement and suggest

300 Comparing FTY720 and FTY720-P with S1P, we show that unlike S1P, the sphingosine analogs do